| Subject | Predicate | Object | Context |
|---|---|---|---|
| http://www.reactome.org/bio... | rdf:type | biopax3:Evidence | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:comment | FGFR2 is inhibited by a range of in vitro tyrosine kinase inhibitors, including PD170734 and SU5402 (reviewed in Greulich and Pollock, 2010; Wesche, 2011). In addition, there are a number of FGFR2 inhibitors currently in clinical trials that for treatment of solid malignancies (http://ClinicalTrials.gov). | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:xref | http://identifiers.org/pubm... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:evidenceCode | http://www.reactome.org/bio... | lld:biopax3 |
| http://www.reactome.org/bio... | biopax3:evidence | http://www.reactome.org/bio... | lld:biopax3 |